Literature DB >> 20522049

Long-term follow-up of patients with syncope evaluated by head-up tilt test.

Giulia Domenichini1, Igor Diemberger, Mauro Biffi, Cristian Martignani, Cinzia Valzania, Matteo Bertini, Davide Saporito, Matteo Ziacchi, Angelo Branzi, Giuseppe Boriani.   

Abstract

BACKGROUND: Clinicians may be tempted to consider a positive head-up tilt test (HUTT) an unfavorable prognostic indicator. We investigated whether results of routine HUTT predict long-term recurrence of syncope.
METHODS: We analyzed syncope recurrence at long-term among 107 patients (mean age 51 +/- 20 years) receiving HUTT for diagnostic evaluation of unexplained/suspected neurocardiogenic syncope in our Institute.
RESULTS: HUTT was positive in 76 patients (vasodepressive response, n = 58; cardioinhibitory, n = 5; mixed, n = 13). During a median follow-up of 113 months (range, 7-161), 34 (32%) patients experienced recurrence (24 [32%] with positive HUTT during 110 months (7-159); 10 [32%] with negative HUTT during 120 [22-161] months). Actuarial freedom from recurrence at 10 years did not significantly differ for patients with positive/negative test results (after passive/active phases) or with different positive response patterns (vasodepressive, cardioinhibitory, mixed). By contrast, history of >4 syncopes in the 12 months preceding HUTT stratified risk of recurrence, irrespective of HUTT positivity/negativity. At Cox proportional hazards analysis, history of >4 syncopes in the 12 months preceding HUTT was the single independent risk factor for recurrence both in the overall study population (HR, 1.7; 95% CI, 1.07-2.69) and within the subset of patients who tested positive (HR, 1.83; 95% CI, 1.07-3.17).
CONCLUSIONS: This long-term follow-up study reinforces the concept that a positive HUTT should not be considered an unfavorable prognostic indicator; frequency of recent occurrences may be a more valid predictor.

Entities:  

Mesh:

Year:  2010        PMID: 20522049      PMCID: PMC6932121          DOI: 10.1111/j.1542-474X.2010.00349.x

Source DB:  PubMed          Journal:  Ann Noninvasive Electrocardiol        ISSN: 1082-720X            Impact factor:   1.468


  19 in total

1.  Guidelines on management (diagnosis and treatment) of syncope-update 2004. Executive Summary.

Authors:  Michele Brignole; Paolo Alboni; David G Benditt; Lennart Bergfeldt; Jean-Jacques Blanc; Poul Erik Bloch Thomsen; J Gert van Dijk; Adam Fitzpatrick; Stefan Hohnloser; Jan Janousek; Wishwa Kapoor; Rose Anne Kenny; Piotr Kulakowski; Giulio Masotti; Angel Moya; Antonio Raviele; Richard Sutton; George Theodorakis; Andrea Ungar; Wouter Wieling; Silvia G Priori; Maria Angeles Alonso Garcia; Andrzej Budaj; Martin Cowie; Jaap Deckers; Enrique Fernandez Burgos; John Lekakis; Bertil Lindhal; Gianfranco Mazzotta; João Morais; Ali Oto; Otto Smiseth; Carlo Menozzi; Hugo Ector; Panos Vardas
Journal:  Eur Heart J       Date:  2004-11       Impact factor: 29.983

Review 2.  Clinical practice. Neurocardiogenic syncope.

Authors:  Blair P Grubb
Journal:  N Engl J Med       Date:  2005-03-10       Impact factor: 91.245

3.  Long-term follow-up of children and adolescents with syncope; predictor of syncope recurrence.

Authors:  C Kouakam; G Vaksmann; E Pachy; D Lacroix; C Rey; S Kacet
Journal:  Eur Heart J       Date:  2001-09       Impact factor: 29.983

4.  Syncope recurrence can better be predicted by history than by head-up tilt testing in untreated patients with suspected neurally mediated syncope.

Authors:  W Grimm; M Degenhardt; J Hoffman; V Menz; A Wirths; B Maisch
Journal:  Eur Heart J       Date:  1997-09       Impact factor: 29.983

5.  Lack of efficacy of atenolol for the prevention of neurally mediated syncope in a highly symptomatic population: a prospective, double-blind, randomized and placebo-controlled study.

Authors:  A H Madrid; J Ortega; J G Rebollo; J G Manzano; J G Segovia; A Sánchez; G Peña; C Moro
Journal:  J Am Coll Cardiol       Date:  2001-02       Impact factor: 24.094

6.  Prospective evaluation of patients with syncope: a population-based study.

Authors:  F P Sarasin; M Louis-Simonet; D Carballo; S Slama; A Rajeswaran; J T Metzger; C Lovis; P F Unger; A F Junod
Journal:  Am J Med       Date:  2001-08-15       Impact factor: 4.965

7.  Prognostic value of head-up tilt test with intravenous beta-blocker administration in assessing the efficacy of therapy in patients with vasovagal syncope.

Authors:  Grzegorz Gielerak; Karol Makowski; Marian Cholewa
Journal:  Ann Noninvasive Electrocardiol       Date:  2005-01       Impact factor: 1.468

8.  Long-term outcome of patients with recurrent syncope of unknown cause in the absence of organic heart disease and relation to results of baseline tilt table testing.

Authors:  Konstantinos Gatzoulis; Skevos Sideris; Artemis Theopistou; Hlias Sotiropoulos; Christodoulos Stefanadis; Pavlos Toutouzas
Journal:  Am J Cardiol       Date:  2003-10-01       Impact factor: 2.778

9.  Recurrence of neurocardiogenic syncope without pharmacologic interventions.

Authors:  A Natale; M J Geiger; C Maglio; K H Newby; A Dhala; M Akhtar; J Sra
Journal:  Am J Cardiol       Date:  1996-05-01       Impact factor: 2.778

Review 10.  [Malignant vasovagal syncope: a case of prolonged asystole induced by the "tilt" test and aggravated by therapy with a beta blocker (a clinical case and diagnostic, physiopathologic and therapeutic review)].

Authors:  J Freitas; J Puig; J Campos; J M Garcia; D L Cunha; M J Carvalho; O Costa; M C Gomes; A F Freitas
Journal:  Rev Port Cardiol       Date:  1993-09       Impact factor: 1.374

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.